Tumori最新文献

{"title":"Nuclear expression of AIRE in lung squamous cell carcinoma correlates with immune microenvironment remodeling and poor prognosis.","authors":"Chengyan Wang, Chuhuai Wang, Yuhan Jia, Fangfang Liu, Xun Yuan, Qian Chu","doi":"10.1177/03008916261423494","DOIUrl":"10.1177/03008916261423494","url":null,"abstract":"<p><strong>Objective: </strong>The autoimmune regulator (AIRE), an atypical transcriptional regulator, exhibits aberrant expression in multiple tumor types. However, its significance in lung squamous cell carcinoma (LUSC) is still uncertain. This study investigated AIRE's expression, immune microenvironment association, and prognostic value in LUSC.</p><p><strong>Method: </strong>AIRE expression was analyzed using TCGA database, validated via RT-qPCR/Western blot in LUSC (H1703, SK-MES-1, EBC-1) vs. normal (BEAS-2B) cells. Tissue microarray immunohistochemistry (IHC) quantified nuclear/cytoplasmic AIRE in clinical samples. Clinicopathological correlations, immune infiltration (CIBERSORT), and survival outcomes were assessed. A nomogram integrating nuclear AIRE and clinical factors predicted 1/3/5-year survival (C-index evaluation).</p><p><strong>Result: </strong>AIRE was upregulated in LUSC. Nuclear AIRE was tumor-specific (absent in normal tissue), elevated in inflammatory stroma (6.29 ± 4.57 vs. 3.10 ± 3.66, P < 0.001), and correlated with lymphocyte infiltration (R = 0.437, P < 0.001). High AIRE linked to increased Tregs (P< 0.001) and reduced dendritic cells (P< 0.01). No association with age, stage, or Ki-67 (P > 0.05) was observed. Patients with high AIRE had worse survival (HR = 2.00 [1.02 - 3.93], P = 0.043). The nomogram incorporating nuclear AIRE achieved a C-index of 0.814 for outcome estimation in our cohort.</p><p><strong>Conclusion: </strong>In a LUSC cohort, nuclear AIRE expression is associated with immune microenvironment features and poorer overall survival. However, its incremental prognostic value beyond established clinicopathological variables appears modest, and further external validation and functional studies are warranted.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"134-144"},"PeriodicalIF":2.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147327127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of body mass index on the treatment response to neoadjuvant chemotherapy in patients with breast cancer: A systematic review and meta-analysis.","authors":"Lirong Zhang, Dongmei Lu, Pan Geng, Gang Chen, Yaqing Wang, Juanqin Niu","doi":"10.1177/03008916251410090","DOIUrl":"10.1177/03008916251410090","url":null,"abstract":"<p><strong>Objective: </strong>Many studies have highlighted that elevated body mass index (BMI) not only correlates with an elevated likelihood of developing breast cancer (BC) but may also influence patients' responsiveness to therapeutic regimens and long-term survival outcomes. The impact of BMI on therapeutic response to neoadjuvant chemotherapy (NAC) in patients with BC remains inconclusive. This study seeks to evaluate the effect of BMI on treatment response in the BC population undergoing NAC via a meta-analysis, thereby providing evidence-based support for clinical decision-making.</p><p><strong>Methods: </strong>PubMed, Embase, Web of Science, and the Cochrane Library were thoroughly searched until July 29, 2024. Eligible studies were selected as per predefined eligibility criteria. Data extraction and quality assessment were executed via the Newcastle-Ottawa Scale (NOS). Statistical analyses were enabled by R 4.4.1 and Stata 17.</p><p><strong>Results: </strong>Fifteen studies encompassing 15,235 patients were incorporated. The meta-analysis revealed that in contrast to patients with a normal or low BMI, those who were overweight or obese had a significantly reduced pathlological complete response (pCR) rate (OR: 0.79, p = 0.040). The underweight cohort demonstrated a higher pCR rate in comparison to those with normal BMI (OR: 1.56, p=0.015). Moreover, overweight and obese cohorts displayed a lower pCR rate in contrast to those having normal BMI (OR: 0.83, p < 0.0001).</p><p><strong>Conclusion: </strong>This study indicates that overweight and obese patients tend to exhibit a reduced pCR, highlighting the need for standardized BMI definitions. Future well-designed prospective studies are necessitated to validate these observations.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"102-117"},"PeriodicalIF":2.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes and beliefs of Italian palliative care experts regarding cachexia: A Delphi study.","authors":"Matteo Moroni, Eduardo Bruera, Luca Ghirotto, Gianmarco Priori, Simone Veronese","doi":"10.1177/03008916261418900","DOIUrl":"10.1177/03008916261418900","url":null,"abstract":"<p><strong>Introduction: </strong>Cachexia is a multifactorial syndrome prevalent in advanced illness. Guidelines rarely integrate the relational, multidimensional perspective of palliative care (PC). Addressing this gap is essential to optimize care. To achieve this, national consensus among PC physicians and nurses on principles and priorities for managing cachexia within PC settings is necessary.</p><p><strong>Methods: </strong>A two-round Delphi study was conducted with 43 Italian PC experts (29 physicians, 14 nurses) meeting ⩾10 years' experience criteria. In Round 1, participants answered open-ended questions informed by literature and a prior exploratory study. Qualitative Framework Method analysis generated 28 statements. In Round 2, statements were rated on a 5-point Likert scale; consensus was defined as ⩾90% agreement (scores 4 or 5).</p><p><strong>Results: </strong>Response rates were 82.2% (Round 1) and 95.5% (Round 2). High consensus (⩾90%) from both physicians and nurses was reached for 14 of 28 statements. Unanimous agreement (100%) supported the need for multiprofessional management, assessment of symptom clusters, and reframing the meaning of food in relation to illness stage. Strong agreement was found for dyadic care planning (97.7%), oral care (97.7%), and body image assessment (95.3%). Lower consensus occurred for prioritizing nutritional deficits (55.8%) and routine CRP/prealbumin testing (34.5%), reflecting contextual and prognostic considerations.</p><p><strong>Conclusions: </strong>This study defines core PC-oriented principles for cachexia management: interprofessional collaboration, dyadic engagement, early holistic assessment, and goal-concordant interventions. Findings can inform future clinical guidelines, training, and policy development to address cachexia in advanced illness.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"176-182"},"PeriodicalIF":2.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence, mortality and risk factors of hematologic malignancies in China from 1990 to 2021: A systematic analysis for the GBD 2021.","authors":"DongHui Gan, Jun Lin, JinFang Zeng, JinQing Fan, ZhiQun Pan","doi":"10.1177/03008916251410092","DOIUrl":"10.1177/03008916251410092","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to systematically analyze the incidence, mortality, and risk factors of hematologic malignancies and their subtypes in China from 1990-2021.</p><p><strong>Methods: </strong>The study utilized data from the Global Burden of Disease 2021 database. Trends in incidence and mortality rates of hematologic malignancies from 1990-2021 were measured using estimated annual percentage change (EAPC) with 95% confidence intervals. Future burden in China up to 2035 was projected using Bayesian age-period-cohort modeling.</p><p><strong>Results: </strong>Between 1990 and 2021, China saw rising age-standardized incidence rates for multiple myeloma, non-Hodgkin lymphoma, and leukemia, but a decline for Hodgkin lymphoma. Mortality decreased for leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma, while increasing for multiple myeloma. Among leukemia subtypes, incidence fell for acute myeloid, chronic myeloid, and other leukemias but rose for acute and chronic lymphoid leukemias. Mortality declined across all five subtypes. Males had higher incidence and mortality than females for all hematologic malignancies. The 65-69 age group had the highest number of cases and deaths. Children under 5 years of age were most affected by leukemia, mainly acute lymphoid leukemia. High BMI was a significant risk factor. Projections to 2035 suggest continued increases in incidence and mortality for multiple myeloma, but declining leukemia mortality. Incidence of acute lymphoblastic and other leukemias is expected to fall, with mortality improving for all leukemia subtypes.</p><p><strong>Conclusions: </strong>China's hematologic malignancy burden remained high in 2021 and is projected to persist through 2035. BMI is a key driver, highlighting the need for targeted control measures to reduce this burden.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"145-156"},"PeriodicalIF":2.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146030990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forceful survivorship: The desire to procreate in parents of cancer patients.","authors":"Annarita Adduci, Giovanna Sironi, Andrea Ferrari, Paolo Grampa, Luca Bergamaschi, Cristina Meazza, Marta Podda, Susanna Castelli, Maura Massimino","doi":"10.1177/03008916251414313","DOIUrl":"10.1177/03008916251414313","url":null,"abstract":"<p><p>Our study evaluated the desire to procreate of 96 mothers of children treated for cancer at the Pediatric Oncology Unit of Istituto Nazionale Tumori of Milan in 2021. Even at a time during which they fear losing the child they already have, nearly one in four mothers expressed their desire to have another child.This wish emerged within a complex interplay of individual, relational, and sociocultural factors. Notably, cultural expectations surrounding motherhood, self-sacrifice, and the ideal of the \"good mother\" appeared to intensify feelings of guilt associated with procreative desire in the context of anticipatory grief. Future cross-cultural investigations could clarify how norms regarding motherhood and reproductive choices differ across societies and influence this phenomenon.Our results also showed a relation between mother's age, children's age, stage of disease and presence of siblings: procreative desire was mainly expressed by younger mothers with only one child, in preschool age and with a bad prognosis.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"97-101"},"PeriodicalIF":2.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported financial toxicity within Italian public healthcare system: A cross-sectional analysis in patients with cancer.","authors":"Anna Amela Valsecchi, Pamela Festa, Maria Laura Malgarini, Giorgia Novero, Chiara Pallisco, Paola Sabbadini, Silvia Beatrice, Marinella Mistrangelo, Gloria Mittica, Alessandra Beano, Francesco Perrone, Massimo Di Maio","doi":"10.1177/03008916261417280","DOIUrl":"10.1177/03008916261417280","url":null,"abstract":"<p><strong>Purpose: </strong>The PROFFIT questionnaire was previously developed and validated, to assess financial toxicity (FT) in Italian patients with cancer. Here we describe FT in patients treated in a public Italian institution in 2024, with a focus on potential determinants of the problem.</p><p><strong>Methods: </strong>PROFFIT was administered cross-sectionally to outpatients undergoing cancer therapy at AOU Città della Salute e della Scienza, Turin. Analysis was descriptive. Multivariate analysis explored association between clinical/demographic features, PROFFIT determinants and PROFFIT score.</p><p><strong>Results: </strong>From October 2024 to December 2024, 359 patients filled in PROFFIT. Median PROFFIT score (0-100 scale) was 33.3 (IQR 14.3-52.4). One hundred and twenty five patients (35%) declared that illness reduced their financial resources. One hundred and three patients (29%) felt that their economic situation affects the possibility of receiving medical care; 124 (35%) felt that National Health Service does not cover all disease costs; 162 (46%) declared payments for private medical exams, 204 (56%) for additional medicines/supplements, 144 (40%) for additional treatments. PROFFIT score was significantly higher in younger patients, in those with worse educational level, in divorced/unmarried patients, in those with economically dependent family members, and in unemployed patients. PROFFIT score was higher for patients with a longer distance to travel to the hospital, although it was not statistically significant. At multivariate analysis, characteristics associated with PROFFIT score were educational level, economically dependent family members, employment status and time from diagnosis; PROFFIT determinants associated with PROFFIT score were payments for additional medicines, payments for additional treatments and travel expenses.ConclusionsEven within the Italian public health system, FT is not negligible among patients with cancer.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"164-175"},"PeriodicalIF":2.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147285139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital workload in oncology trials: A comparative analysis of e-portal usage and operational insights from a single-center experience.","authors":"Stefano Stabile, Sara Mariano, Anna Bombelli, Noemi Salmistraro, Letizia Monti, Giovanna Marrapese, Silvia Ghezzi, Francesca Pelle, Federica Rungo, Sabrina Carolei, Salvatore Siena","doi":"10.1177/03008916251412105","DOIUrl":"10.1177/03008916251412105","url":null,"abstract":"<p><strong>Background: </strong>The digitalization of clinical research has increased reliance on electronic portals (e-portals), with significant implications for trial site operations. Our aim is to map the types and number of e-portals required for clinical trials on solid tumors conducted at the Niguarda Cancer Center.</p><p><strong>Methods: </strong>We performed an aggregated analysis of 65 interventional drug trials (phase I-III) initiated between August 2022 and March 2025. For each study, the number and type of e-portals required at the site were recorded and stratified by sponsor type. Analyses were conducted using R.</p><p><strong>Results: </strong>A total of 65 trials were included (57 industry-sponsored, 8 academic). The mean number of e-portals per study was 5.3, with 66.1% of trials requiring 5-7 portals. Industry-sponsored trials employed significantly more e-portals than academic ones (mean ± SD: 5.8 ± 1.7 vs. 1.13 ± 0.35; t(41)=22.10, p<0.0001). Electronic Data Capture (EDC) systems were universally implemented (100%). Additional portals for randomization (IXRS), central laboratories, imaging, and safety reporting were common in industry-sponsored trials but rarely used in academic studies. Patient-reported outcomes (PROs) were included in ~49% of industry and 88% of academic trials; 89% of PROs in industry studies were captured via ePRO portals, while academic trials mostly relied on paper forms or EDC integration.</p><p><strong>Conclusions: </strong>Industry-sponsored oncology trials impose a high digital workload on sites. Vendor streamlining, single sign-on solutions, open API standards, and shared ePRO infrastructures could improve efficiency, interoperability, and data quality.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"157-163"},"PeriodicalIF":2.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety evaluation of selective RET inhibitors in patients with lung cancer: a real-world pharmacovigilance study.","authors":"Yaokai Wang, Wenmei Jiang, Yun Cheng, Qian Dong, Junnan Ru, Chang Yu, Jue Shen, Leilei Wu","doi":"10.1177/03008916251414316","DOIUrl":"10.1177/03008916251414316","url":null,"abstract":"<p><strong>Objectives: </strong>Selpercatinib and pralsetinib are targeted therapies for non-small cell lung cancer. However, their adverse reaction profiles remain incompletely understood. This study aims to evaluate the post-marketing adverse events (AEs) associated with selpercatinib and pralsetinib in real-world populations.</p><p><strong>Methods: </strong>We conducted a comprehensive analysis of AEs linked to selective RET inhibitors using advanced data mining techniques on the FDA Adverse Event Reporting System. Disproportionality analysis was performed to quantify the association between these drugs and AEs. Key metrics for disproportionality assessment included the reporting odds ratio (ROR), proportional reporting ratio, information component, and empirical Bayesian geometric mean.</p><p><strong>Result: </strong>A total of 522 and 917 AE reports were identified for selpercatinib and pralsetinib in lung cancer patients, with 209 and 312 preferred terms recorded for each drug. The most frequent AEs for selpercatinib included hepatobiliary disorders (ROR=10.71) and cardiac disorders (ROR=2.33). For pralsetinib, the most common AEs were hepatobiliary disorders (ROR=2.57) and gastrointestinal disorders (ROR=1.53). Compared to pralsetinib, selpercatinib had a more increased risk of serious outcomes (P<0.05).</p><p><strong>Conclusion: </strong>This study provides critical insights into the established and potential adverse events associated with selpercatinib and pralsetinib. The findings offer valuable evidence to guide the clinical use of RET inhibitors.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"124-133"},"PeriodicalIF":2.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146126379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life and sexual function after breast conservation surgery and mastectomy without reconstruction in South Indian patients.","authors":"Silviya Jenifer, Sneha Raja, Narmatha Rajarathinam, Jayasutha Jayram, Manickavasagam Meenakshisundaram","doi":"10.1177/03008916261425451","DOIUrl":"10.1177/03008916261425451","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is a leading malignancy among women worldwide, significantly affecting physical, psychological, and sexual well-being. Surgical options such as breast conservation surgery (BCS) and mastectomy have distinct implications on patients' quality of life. This study aimed to compare health-related quality of life (HRQoL) and sexual functioning in breast cancer patients undergoing BCS or mastectomy.</p><p><strong>Methods: </strong>A prospective observational study was conducted over a 10-month period at a tertiary care hospital. Sixty-five breast cancer patients aged 20-50 years, who underwent either BCS (n=33) or mastectomy (n=32), were enrolled. Data were collected on baseline characteristics and HRQoL and sexual functioning were assessed using the EORTC QLQ-BR42 and Female Sexual Function Index (FSFI) questionnaires.</p><p><strong>Results: </strong>BCS patients reported significantly better scores in FSFI domains such as desire, lubrication, orgasm, and satisfaction (p<0.05), with a higher final FSFI score (5.53 ± 1.78) compared to mastectomy patients (3.93 ± 1.06). On the BR42 scale, BCS patients showed better body image and satisfaction scores (p<0.05). No significant differences were observed in systemic side effects, future health worries, and sexuality domains between the groups.</p><p><strong>Conclusion: </strong>Breast conservation surgery patients had better sexual function and quality of life compared to mastectomy patients. These findings underscore the importance of incorporating quality-of-life outcomes in surgical decision-making and preoperative counseling for breast cancer patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"118-123"},"PeriodicalIF":2.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147327132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of combined adjuvant strategies for tumor biomarker detection.","authors":"JianKun Liang, XiaoWen Xin, Ai Chen, Wei Li, ZhenLong Sun, Nan Wang, Peng Liu, MingYi Wang","doi":"10.1177/03008916261425908","DOIUrl":"https://doi.org/10.1177/03008916261425908","url":null,"abstract":"<p><p>Cancer is one of the leading causes of death worldwide, and early tumor detection can significantly reduce mortality rates. Liquid biopsy is a minimally invasive, repeatable method with a high economic benefit ratio, and it shows excellent prospects for tumor diagnosis. However, the detection methods relying on classical biomarkers have limited sensitivity and accuracy. The application of auxiliary reagents, such as iRGD, promotes the release of alpha-fetoprotein (AFP) to improve the detection efficiency of liver cancer. Artificial intelligence (AI) technology is increasingly being applied as an assistant in tumor diagnosis. It can automatically identify tumor lesions in imaging, analyze tumor-related gene mutations, classify circulating tumor cells (CTCs), and integrate multi-omics data. These auxiliary means have enhanced the efficiency of tumor screening or detection. In this review, we summarize the combined applications of iRGD and AFP. We also discuss emerging new detection techniques, including CTCs, circulating tumor DNA (ctDNA), exosomes, and tumor-educated platelets (TEPs), specifically with the help of AI. The aim is to better understand the auxiliary role of the iRGD reagent and AI technology in early tumor detection.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261425908"},"PeriodicalIF":3.1,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147445276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}